Enhanced levels of both the membrane-bound and soluble forms of IgM Fc receptor (FcμR) in patients with chronic lymphocytic leukemia

Blood

Volumn 118, Issue 18, 2011, Pages 4902-4909

  Li, Fu Jun ^a   Kubagawa, Yoshiki ^b   McCollum, Matthew K ^b   Wilson, Landon ^c   Motohashi, Tomoko ^b   Bertoli, Luigi F ^d   Barton, James C ^d   Barnes, Stephen ^c   Davis, Randall S ^a   Kubagawa, Hiromi ^b  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c University of Alabama at Birmingham   (United States)

^d Brookwood Medical Center Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; IMMUNOGLOBULIN M; MEMBRANE RECEPTOR; RAL PROTEIN;

ARTICLE; B LYMPHOCYTE; BLOOD LEVEL; CELL SURFACE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; HUMAN CELL; LYMPHOCYTE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

EID: 80855133518     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-04-350793     Document Type: Article

References (49)

1. Stevenson FK, Caligaris-Cappio F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood. 2004;103(12):4389-4395. (Pubitemid 38745961)
2. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352(8): 804-815.
3. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94(6):1840-1847. (Pubitemid 29430399)
4. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94(6):1848-1854. (Pubitemid 29430400)
5. Kröber A, Seiler T, Benner A, et al. VH mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood. 2002;100(4):1410-1416. (Pubitemid 34864299)
6. Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001;194(11): 1639-1647. (Pubitemid 33126814)
7. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulinvariable- region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348(18):1764-1775. (Pubitemid 36514707)
8. Wiestner A, Rosenwald A, Barry TS, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood. 2003;101(12):4944-4951. (Pubitemid 36857758)
9. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004;351(9):893-901. (Pubitemid 39096916)
10. Orchard JA, Ibbotson RE, Davis Z, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet. 2004;363(9403):105-111. (Pubitemid 38068326)
11. Del Principe MI, Del PG, Buccisano F, et al. Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. Blood. 2006; 108(3):853-861. (Pubitemid 44154617)
12. Ibrahim S, Keating M, Do KA, et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood. 2001;98(1): 181-186.
13. Del Poeta G, Maurillo L, Venditti A, et al. Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood. 2001;98(9):2633-2639.
14. Hamblin TJ, Orchard JA, Ibbotson RE, et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood. 2002;99(3):1023-1029. (Pubitemid 34525567)
15. Li FJ, Ding S, Pan J, et al. FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia. Blood. 2008;112(1):179-187.
16. Meuleman N, Stamatopoulos B, Dejeneffe M, et al. Doubling time of soluble CD23: a powerful prognostic factor for newly diagnosed and untreated stage A chronic lymphocytic leukemia patients. Leukemia. 2008;22(10):1882-1890.
17. Montillo M, Hamblin T, Hallek M, Montserrat E, Morra E. Chronic lymphocytic leukemia: novel prognostic factors and their relevance for riskadapted therapeutic strategies. Haematologica. 2005;90(3):391-399. (Pubitemid 40388989)
18. Pichler WJ, Knapp W. Receptors for IgM-coated erythrocytes on chronic lymphatic leukemia cells. J Immunol. 1977;118(3):1010-1015. (Pubitemid 8064689)
19. Ferrarini M, Hoffman T, Fu SM, Winchester R, Kunkel HG. Receptors for IgM on certain human B lymphocytes. J Immunol. 1977;119(4):1525- 1529.
20. Burns GF, Cawley JC, Barker CR. Characterization of the receptor for IgM present on human B lymphocytes. Immunology. 1979;36(3):569- 577.
21. Rudders RA, Andersen J, Howard JP, Fried R. The binding of IgM to B lymphocytes. I. Studies of the binding of aggregated IgM to normal and leukemic human B lymphocytes. Clin Immunol Immunopathol. 1980;15(4):673-686. (Pubitemid 10181911)
22. Platsoucas CD, Kempin S, Karanas A, et al. Receptors for immunoglobulin isotype on T and B lymphocytes from untreated patients with chronic lymphocytic leukaemia. Clin Exp Immunol. 1980; 40(2):256-263. (Pubitemid 10113458)
23. Sanders SK, Kubagawa H, Suzuki T, Butler JL, Cooper MD. IgM binding protein expressed by activated B cells. J Immunol. 1987;139(1):188- 193.
24. Ohno T, Kubagawa H, Sanders SK, Cooper MD. Biochemical nature of an Fcmu receptor on human B-lineage cells. J Exp Med. 1990;172(4): 1165-1175. (Pubitemid 20343217)
25. Kubagawa H, Oka S, Kubagawa Y, et al. Identity of the elusive IgM Fc receptor (FcμR) in humans. J Exp Med. 2009;206(12):2779-2793.
26. Hitoshi Y, Lorens J, Kitada SI, et al. Toso, a cell surface, specific regulator of Fas-induced apoptosis in T cells. Immunity. 1998;8(4):461-471. (Pubitemid 28196800)
27. Proto-Siqueira R, Panepucci RA, Careta FP, et al. SAGE analysis demonstrates increased expression of TOSO contributing to Fas-mediated resistance in CLL. Blood. 2008;112(2):394-397.
28. Pallasch CP, Schulz A, Kutsch N, et al. Overexpression of TOSO in CLL is triggered by B-cell receptor signaling and associated with progressive disease. Blood. 2008;112(10):4213-4219.
29. Pallasch CP, Wendtner CM. Overexpression of the Fas-inhibitory molecule TOSO: a novel antiapoptotic factor in chronic lymphocytic leukemia. Leuk Lymphoma. 2009;50(3):498-501.
30. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87(12):4990-4997. (Pubitemid 26189840)
31. Wang J, Coombes KR, Highsmith WE, Keating MJ, Abruzzo LV. Differences in gene expression between B-cell chronic lymphocytic leukemia and normal B cells: a meta-analysis of three microarray studies. Bioinformatics. 2004;20(17):3166- 3178.
32. Catera R, Silverman GJ, Hatzi K, et al. Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation. Mol Med. 2008;14(11-12):665-674.
33. Klein U, Tu Y, Stolovitzky GA, et al. Transcriptional analysis of the B cell germinal center reaction. Proc Natl Acad Sci U S A. 2003;100(5): 2639-2644. (Pubitemid 36297551)
34. Hoover RG, Dieckgraefe BK, Lynch RG. T cells with Fc receptors for IgA: induction of T alpha cells in vivo and in vitro by purified IgA. J Immunol. 1981;127(4):1560-1563. (Pubitemid 11021043)
35. Reljic R. In search of the elusive mouse macrophage Fcalpha receptor. Immunol Lett. 2006; 107(1):80-81. (Pubitemid 44332542)
36. Maruoka T, Nagata T, Kasahara M. Identification of the rat IgA Fc receptor encoded in the leukocyte receptor complex. Immunogenetics. 2004; 55(10):712-716. (Pubitemid 38221671)
37. Stevenson FK, Hamblin TJ, Stevenson GT, Tutt AL. Extracellular idiotypic immunoglobulin arising from human leukemic B lymphocytes. J Exp Med. 1980;152(6):1484-1496. (Pubitemid 11210330)
38. Qian GX, Fu SM, Solanki DL, Rai KR. Circulating monoclonal IgM proteins in B cell chronic lymphocytic leukemia: their identification, characterization and relationship to membrane IgM. J Immunol. 1984;133(6):3396-3400. (Pubitemid 15216524)
39. Bertoli LF, Kubagawa H, Borzillo GV, et al. Analysis with antiidiotype antibody of a patient with chronic lymphocytic leukemia and a large cell lymphoma (Richter's syndrome). Blood. 1987; 70(1):45-50. (Pubitemid 17111239)
40. Fayad L, Keating MJ, Reuben JM, et al. Interleukin- 6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood. 2001;97(1):256-263. (Pubitemid 32061268)
41. Ramsay AG, Johnson AJ, Lee AM, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest. 2008;118(7):2427-2437. (Pubitemid 351949771)
42. Gu B, Bendall LJ, Wiley JS. Adenosine triphosphate- induced shedding of CD23 and L-selectin (CD62L) from lymphocytes is mediated by the same receptor but different metalloproteases. Blood. 1998;92(3):946-951. (Pubitemid 28355478)
43. Sarfati M, Chevret S, Chastang C, et al. Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia. Blood. 1996; 88(11):4259-4264. (Pubitemid 26399173)
44. Albitar M, Do KA, Johnson MM, et al. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. Cancer. 2004; 101(5):999-1008. (Pubitemid 39100434)
45. Alfarano A, Indraccolo S, Circosta P, et al. An alternatively spliced form of CD79b gene may account for altered B-cell receptor expression in B-chronic lymphocytic leukemia. Blood. 1999; 93(7):2327-2335.
46. Cragg MS, Chan HT, Fox MD, et al. The alternative transcript of CD79b is overexpressed in BCLL and inhibits signaling for apoptosis. Blood. 2002;100(9):3068-3076. (Pubitemid 35217051)
47. Sharma S, Lichtenstein A. Aberrant splicing of the E-cadherin transcript is a novel mechanism of gene silencing in chronic lymphocytic leukemia cells. Blood. 2009;114(19):4179-4185.
48. Ghosh AK, Secreto CR, Knox TR, et al. Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression. Blood. 2010; 115(9):1755-1764.
49. Wang GS, Cooper TA. Splicing in disease: disruption of the splicing code and the decoding machinery. Nat Rev Genet. 2007;8(10):749-761. (Pubitemid 47429207)